Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | BRD2 | P25440 | 2/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.30 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.30 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26547726 | 0.83 | KMT2A (0.34) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL31248639 | 0.83 | KMT2A (0.34) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL26547632 | 0.81 | CYP19A1 (0.43) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL26547697 | 0.81 | ALDH1A1 (0.36) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL29471244 | 0.80 | MEN1 (0.43) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL31248637 | 0.79 | BRPF1 (0.43) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL26547712 | 0.79 | HPGD (0.42) | LMNAALDH1A1MEN1KMT2ABRD4 | |
| SCHEMBL31248652 | 0.77 | MEN1 (0.34) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL31248757 | 0.77 | SMN1; SMN2 (0.37) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL26547708 | 0.75 | TNFRSF1A (0.44) | LMNATSHRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | ACACB 163/4885LMNA 1554/4885TSHR 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.